CognitivePrices may be stale · 19d ago

Dihexa

Dihexa is a synthetic compound derived from angiotensin IV, developed at Washington State University and studied as a procognitive agent acting through the hepatocyte growth factor and c-Met system. The foundational research describing this mechanism was retracted in 2025 for data fabrication. No human clinical trial of dihexa has been published.

Lowest cost / mg: $0.28/mg; at Disguised Alpha
Suppliers listed: 11
In stock: 13 of 17; listings
COA reports: 9

Jump to

Overview Supplier Listings Benefits Evidence Interactions FAQ

Supplier listings

Compare Dihexa prices.

Form

Show prices as

Size

8 listings · Dihexa

Amino ClubLowest $/mg
In stock10mgseen 7w ago
$23.99
$29.99$2.40/mg-20%
PRODUCTS
Alpha Peptides
In stock5mgseen 7w ago
$32.21
$35.79$6.44/mg-10%
peplookup
Pure Peptides
In stock10mgseen 4w ago
$42.00
$4.20/mg
Prpeps
In stock10mgseen 7w ago
$40.50
$45.00$4.05/mg-10%
peplookup
Pristine Aminos
In stock10mgseen 7w ago
$65.00
$6.50/mg
NeuroLabs Research
Out of stock10mgseen 2w ago
$68.60
$76.22$6.86/mg-10%
PEPLOOKUP
Void Research
Out of stock10mgseen 7w ago
$76.49
$84.99$7.65/mg-10%
PEPLOOKUP

Overview

What is Dihexa?

Cognitive Support
Memory
Neuroplasticity
Learning

What the research reports

Reported benefits of Dihexa

Outcomes described across the published Dihexa literature and ongoing study. Read each as research context rather than a promised personal result.

01
Synaptogenesis animal study
Claims of new synaptic connection formation originate primarily from a 2014 paper that was retracted in 2025 for fabricated data. No independently verified study currently supports this specific finding.
02
HGF and c-Met pathway work
Dihexa's proposed mechanism involves the hepatocyte growth factor and c-Met receptor system. The foundational paper establishing this mechanism was retracted in 2025 for fabricated data; the mechanism should be considered unconfirmed pending independent replication.
03
High laboratory potency data
Active at very low concentrations in cell based synaptogenesis assays, which is a measure of potency rather than of clinical effect. Reported in research settings.
04
Memory model animal study
Studied in animal models of impaired cognition, including scopolamine induced amnesia and Alzheimer's disease models. Described in the research record.
05
Neuroprotection study note
Reviews propose neuroprotective potential through the same growth factor pathway, though no controlled human data supports this. Reported in research settings.

Clinical evidence

Dihexa clinical evidence summary

The published Dihexa record, labeled by strength so you can see what is settled and what is still emerging.

Retracted mechanism paper, 2014 (2025 retraction)

A foundational 2014 paper describing Dihexa's HGF/c-Met mechanism was retracted in 2025 following a Washington State University investigation that found fabricated data in the original figures. A related 2012 paper by the same research group was also retracted. The mechanistic basis for Dihexa's procognitive claims should be treated as unsettled. Source: link to the retraction notice itself,

Source

Huntington model study 2024

An animal study in 40 rats found that an angiotensin IV analogue did not protect against 3-nitropropionic acid induced Huntington's like symptoms. Reported in the cited paper.

Source

Systematic animal review 2018

A systematic review of experimental studies examined cognitive effects of angiotensin IV and angiotensin 1-7 across the available animal literature. Reported in the cited paper.

Source

Interactions

How Dihexa pairs with other peptides

Semax peptide: Both are studied for cognition by separate mechanisms, with no data on combined administration.
c-Met inhibitors: The proposed basis for this interaction (Dihexa's HGF/c-Met activation) comes from a now-retracted study. This interaction should not be treated as established.
ACE inhibitors: Both touch the renin angiotensin system, so overlap is plausible but has not been formally studied.
Selank peptide: No published interaction data exists for this pairing in either the human or the animal literature.

Questions

Frequently asked questions.

What is Dihexa?

Dihexa is a synthetic compound derived from angiotensin IV, developed at Washington State University and studied as a procognitive agent. It's technically a small molecule rather than a peptide, though it's commonly searched and sold under that label.

Has Dihexa's mechanism been verified?

The foundational 2014 research describing Dihexa's hepatocyte growth factor/c-Met mechanism was retracted in 2025 after a Washington State University investigation found fabricated data in the original figures. The mechanism should currently be considered unconfirmed.

Does Dihexa have human clinical trial data?

No. No human clinical trial of Dihexa has been published. Available evidence is limited to animal and preclinical studies, and some of the earliest foundational research has since been retracted.

Does Dihexa research include dosage information?

PepLookup doesn't publish dosing guidance for any compound. The Evidence section on this page cites what's actually been published, including its limitations, the appropriate source for research purposes.

Does PepLookup sell Dihexa?

No. PepLookup is a comparison tool. We list publicly published prices from suppliers so they can be compared side by side. Every order is placed on the supplier's own site.

Dihexa

Lowest cost / mg

$0.28/mg

at Disguised Alpha

Suppliers listed

In stock

13 of 17

listings

COA reports

What is Dihexa?

Cognitive Support

Memory

Neuroplasticity

Learning

Reported benefits of Dihexa

Outcomes described across the published Dihexa literature and ongoing study. Read each as research context rather than a promised personal result.

Synaptogenesis animal study

Claims of new synaptic connection formation originate primarily from a 2014 paper that was retracted in 2025 for fabricated data. No independently verified study currently supports this specific finding.

HGF and c-Met pathway work

Dihexa's proposed mechanism involves the hepatocyte growth factor and c-Met receptor system. The foundational paper establishing this mechanism was retracted in 2025 for fabricated data; the mechanism should be considered unconfirmed pending independent replication.

High laboratory potency data

Active at very low concentrations in cell based synaptogenesis assays, which is a measure of potency rather than of clinical effect. Reported in research settings.

Memory model animal study

Studied in animal models of impaired cognition, including scopolamine induced amnesia and Alzheimer's disease models. Described in the research record.

Neuroprotection study note

Reviews propose neuroprotective potential through the same growth factor pathway, though no controlled human data supports this. Reported in research settings.

Dihexa clinical evidence summary

The published Dihexa record, labeled by strength so you can see what is settled and what is still emerging.

Retracted mechanism paper, 2014 (2025 retraction)

Source

Huntington model study 2024

An animal study in 40 rats found that an angiotensin IV analogue did not protect against 3-nitropropionic acid induced Huntington's like symptoms. Reported in the cited paper.

Source

Systematic animal review 2018

A systematic review of experimental studies examined cognitive effects of angiotensin IV and angiotensin 1-7 across the available animal literature. Reported in the cited paper.

Source

How Dihexa pairs with other peptides

Semax peptide

Both are studied for cognition by separate mechanisms, with no data on combined administration.

c-Met inhibitors

The proposed basis for this interaction (Dihexa's HGF/c-Met activation) comes from a now-retracted study. This interaction should not be treated as established.

ACE inhibitors

Both touch the renin angiotensin system, so overlap is plausible but has not been formally studied.

Selank peptide

No published interaction data exists for this pairing in either the human or the animal literature.